9,854 trials (keyword fallback)
Chronic Phase Myelofibrosis · Primary Myelofibrosis · Post-essential Thrombocythemia Myelofibrosis
Primary: European Leukemia Net -International Working Group (ELN-IWG) Criteria — 0 Participants
Chronic Myelomonocytic Leukemia-2 · Myelodysplastic Syndrome · Myeloproliferative Neoplasm
Primary: Overall Survival of Patients Over Age 60 With Newly Diagnosed AML/High Risk MDS — 7 participants
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Rates of Complete Remission and Complete Remission With Incomplete Recovery of Counts — 38; 33; 41; 23 Participants
Myelodysplastic Syndromes
Primary: The Number of Patients With Grade 3 or Higher Serious Adverse Events. — 3 Participants
Anemia · Myelodysplastic/Myeloproliferative Neoplasm · Myelofibrosis
Primary: Anemia-response — 8; 6 Participants
Primary Myelofibrosis · MPN-associated Myelofibrosis
Primary: Percentage of Participants Who Achieved RBC-Transfusion Independence — 17.3; 16.7 percentage of participants — p=1.000
Blast Injuries · Brain Injuries · Age Factors
Primary: Number of Blast-exposed Veterans With Abnormal Abilities in One or More Behavioral Tests of Central Auditory Processing — 99.1; 95.2; 96.6; 97.5 units on a scale
Accelerated/Blast-phase Myeloproliferative Neoplasm · Chronic-phase Myelofibrosis · IDH2 Mutation
Primary: Number of MPN Participants With Response — 2 Participants
Accelerated Phase Chronic Myelogenous Leukemia · Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative · Blastic Phase Chronic Myelogenous Leukemia
Primary: Response Rate Including Complete Response, Partial Response, and Hematological Improvement Assessed by Blood Cell Counts, Number of Blasts in Bone Marrow, and Clinical…
Chronic Myelogenous Leukemia · Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) · Hypereosinophilic Syndrome
Primary: Number of Participants With Major Cytogenetic Response (MCyR) — 191; 44; 22 Participants
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Thrombocythemia, Essential · Primary Myelofibrosis
Primary: Percentage of Participants Who Experience an Adverse Event (AE) — 98.1; 100.0 Percentage of Participants
Primary Myelofibrosis (PMF) · Post-Polycythaemia Vera · Essential Thrombocythaemia Myelofibrosis
Primary: Pharmacokinetic Parameters Following Single Dosing: AUC0-12 — 69.2; 295; 278; 1860 ug*h/L
Pancreatic Carcinoma
Primary: Percentage of Patients Discharged by Post-operative Day 5 — 5; 28 Participants
Primary Myelofibrosis · Anemia
Primary: The Number of Participants With Anemia Responses Over Any 84-Day Period During the Primary Treatment Period — 3; 2; 2; 10 Participants